Podcasts about GBM

Send us a textThe Accelerators co-host Dr. Matt Spraker is joined by two experts in brachytherapy for brain tumors, Radiation Onocologist and CMO of GT Medical Technologies Dr. Michael Garcia, MD, MS and Neurosurgeon Dr. Simon Hanft, MD, FAANS.We first review the origin story of GammaTile, an evolution of the practice of brachytherapy for brain tumors. Simon then shares how he has deployed GammaTile in his practice. We dive in to patient selection, how the design facilitates a shallow technical learning curve, and the process of prescribing and placing the implant.Discussion then shifts to research. We review some of the published studies (see links below) that support use of GammaTile for both brain metastases and recurrent primary brain tumors, such as GBM and meningioma. We also discuss some recently completed and soon-to-open trials, including Mike's creative idea - time intensification! -  to move the needle on outcomes for glioblastoma. Here are some of the studies we discussed and other useful links:The ROADS Study The GESTALT StudyEkhator et al., Review of GammaTile Studies Prasad et al., Radiation Protection Considerations for GammaTileGriffin et al., Fast Neutron Therapy for GBMBeckham et al., GammaTile for Salvage of Recurrent Brain Mets and a nice industry summary of findings in context (BioSpace)Dr. Simon Hanft, Building a Successful GammaTile Program (YouTube)A nice Insta patient video by a Dr. Bohnen, a neurosurgeon at Matt's centerEditor's Note: TAP were compensated for this episode and GT Medical Technologies participated in planning the content. The discussions in this episode are the opinions of the participants and are not clinical advice.Please see our website for complete information on our past and current sponsors.The Accelerators Podcast is a Photon Media production. 

Overview of the prophecy of Zephaniah, one of the minor prophets in the Old Testament. #MinorProphets #sermon #preaching #Zephaniah #Godsgrace #Godsmercy #Josiah #wrathofGod #Godspurposes #FaithfulRemnant #blessingallnations #fulfilledinChrist #Gentiles #honourofhisname #2Chronicles34v3 #Psalm126v1 #Zephaniah2v1-3 #Zephaniah2v11 #Zephaniah3v9-20 #Romans1v18 A Pastor Talks brings God's word to bear on all aspects of the Christian experience. #Pastor #Pastoral #Forgetit #Forgiveness #forgive #angry #unforgiving #peace #Ephesians4v32 #Colossians3v13 For more audio from GBM, visit gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Welcome to the Christian's Hour Program! TCH is a ministry of Gospel Broadcasting Mission. GBM's mission is to broadcast the message of Jesus, in their own language, to unreached people groups and tribes world-wide.Just like threats to national security, we need to be on high alert for threats in our own lives. Spiritually, what we're up against, isn't always visible. The enemy's tactics, are subtle, strategic, and deadly. Exposing these threats, staying alert against them, and guarding our hearts are key to winning the battle against these “Kingslayers.”This month, Mike Breaux, a teaching minister with Eastside Christian Church in Anaheim, California has been digging into the lives of several Biblical kings who were “taken out” from the inside out. Pride, Envy, Disobedience, are threats that were at the root of the undoing of powerful men; and they lurk in our lives as well. Pharaoh wanted the last word, so when faced with the power of the Almighty and a way out, he said “tomorrow”. The root causes of Procrastination takes many forms, and control by saying “tomorrow” is just one of them. With a more complete list and some ways to combat this Kingslayer, here's Mike… To support this ministry financially, visit: https://www.oneplace.com/donate/326/29

Overview of the prophecy of Zephaniah, one of the minor prophets in the Old Testament. #MinorProphets #sermon #preaching #Zephaniah #Hezekiah #Josiah #judgment #Judah #Babylonians #Nebuchadnezzar #Godsanger #idolatry #arbitrary #professingchurch #finalday #Christ #Zephaniah1-2 #2Peter3v1-7 Bill James takes us through the incommunicable attributes of God, the characteristics in which God differs from us. #doctrine #summaryofBible #attributesofGod #incommunicable #promises #prophecies #faithfulGod #faithfulness #covenants #neverforsake #grace #eternity #Exodus3v14 #Matthew14v27 #John6v35 #John8v12,58 #John10v7 #John14v6 #2Corinthians1v20 For more audio from GBM, visit gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Overview of the prophecy of Habakkuk, one of the minor prophets in the Old Testament. #MinorProphets #sermon #preaching #Habakkuk #finalprayer #Godsmightyacts #deliverance #mercy #judgment #fulfilment #Belshazzar #Babylon #Daniel #Persians #Providences #Habakkuk3 Bill James takes us through the incommunicable attributes of God, the characteristics in which God differs from us. #doctrine #summaryofBible #attributesofGod #incommunicable #Moses #God #burningbush #covenantpromises #commitment #unfailing #merciful #purposes #dependable #Exodus3v15-16 For more audio from GBM, visit gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

.This is the Christian's Hour Broadcast.TCH is a ministry of Gospel Broadcasting Mission. GBM's mission is to broadcast the message of Jesus, in their own language, to unreached people groups and tribes world-wide.While governments conduct surveillance to protect their leaders from outside threats, sometimes the real danger is from within. And the same is true for us personally! What we're up against isn't always visible. The spiritual enemy's tactics are subtle, strategic, and deadly.This month, Mike Breaux, a teaching minister with Eastside Christian Church in Anaheim, California is digging into the lives of several Biblical kings who were “taken out”—not by an external force, but from the inside out. Pride, Envy, Disobedience, are threats that were at the root of the undoing of powerful men and they lurk in our lives as well.The first king of Israel, King Saul, went from celebrating the victory of the giant Goliath's defeat by a boy named David to plotting David's destruction after hearing just one song. So, here's Mike to take us to def-con 3 when it comes to the dangers of Envy. To support this ministry financially, visit: https://www.oneplace.com/donate/326/29

Host Dr. Shannon Westin and guest Dr. Hani Babiker discuss the JCO article "Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." TRANSCRIPT TTFields in Locally Advanced Pancreatic Adenocarcinoma Dr. Shannon Westin: Hello everyone, and welcome to another episode of JCO After Hours, the podcast where we get in depth with manuscripts that have been published in the Journal of Clinical Oncology. I am your host, gynecologic oncologist Shannon Westin, social media editor at the JCO, and just excited to be here to learn today about pancreatic cancer. None of our participants have conflicts of interest related to this podcast, and it is my honor to introduce Dr. Hani Babiker. He is an associate professor of medicine, consultant in oncology at the Mayo Clinic in Jacksonville, Florida. Welcome, Dr. Babiker. Dr. Hani Babiker: Hi, Dr. Westin. Thank you for the great opportunity to discuss our trial, and thank you for having me here. I really appreciate it, and I am excited. Dr. Shannon Westin: All right, so are we. So we are going to be talking about “Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: A Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study.” This was simultaneously published and presented in the JCO and at the annual meeting of ASCO on 5/31/2025. So, let's level set. Can you speak to us just a little bit about pancreatic cancer? What is the survival, and what is the typical treatment for locally advanced disease? This gynecologic oncologist has not kept up in this field. Dr. Hani Babiker: Absolutely, Dr. Westin, and thank you for that question. Pancreatic adenocarcinoma is a lethal cancer. When I first started my career, the 5-year survival, per the Surveillance, Epidemiology, and End Results, was at 4.5%. I always, whenever I was giving talks, say that I really hope that I will see it in the double digit. Now, the 5-year survival for all pancreatic adenocarcinoma is 13.3%. And the 5-year survival, and although it is a double digit, I still hope that I will see it in a higher double digit in the future. It is even worse in patients with metastatic cancer, about 3% 5-year survival for metastatic pancreatic cancer. It is a dismal diagnosis. I really hope in the future we will find a better therapeutic approach to this lethal cancer. Dr. Shannon Westin: Yes, I just lost a very dear friend and colleague to this disease, so I completely agree with you. Well, now that we are settled kind of with the basics here, I would love to talk a little bit about kind of the primary piece of this intervention, the Tumor Treating Fields. So, how does this work? And what diseases has it gotten indications in as yet? Dr. Hani Babiker: Absolutely. So, Tumor Treating Fields is alternating frequency electrical fields that have been studied preclinically and shown that it abrogates cancer cell proliferation. Earlier on, we knew that it inhibits polymerization of tubulin, and hence, it affects cancer cells from proliferating. Later, we are learning that there are multiple mechanisms of action. It affects permeability, allowing for better drug delivery. It also inhibits cancer cell proliferation through affecting autophagy mechanisms that pancreatic cancer cells will use for proliferating and becoming more aggressive. There is also some early data preclinically in colorectal cancer cell lines and lung cancer cell lines and in vivo models showing that it potentially could activate the microenvironment to make it more pro-immunogenic. We recently published papers showing that it could also affect the nanomechanical properties of the tumor microenvironment within pancreatic cancer, hinting towards affecting, potentially, the stroma. So, there are multiple mechanisms to Tumor Treating Electric Fields. It is a new, novel therapeutic approach. Sometimes when I speak with my trainees, I say, "Well, we have surgery, we have radiation and chemotherapy, and this is something new." Tumor Treating Fields initially was studied in refractory GBM and got an indication there. Subsequently, frontline treatment of GBM in a randomized clinical trial, and then malignant pleural mesothelioma and non-small cell lung cancer. We have studied it in pancreatic cancer. Dr. Shannon Westin: I don't think I have ever heard it described so perfectly. That was brilliant. So thank you, and I hope everyone listening knows that you just got a masterclass on this mechanism. You know, they dabbled in it a little bit in ovarian cancer and it didn't quite make the grade, so I was a little definitely disappointed. But very excited about the data we're going to talk about today. So let's get into the PANOVA-3 study. Can you highlight the overall design and also the key eligibility criteria that would be helpful for our listeners? Dr. Hani Babiker: Absolutely. So, it started off with preclinical work in pancreatic cancer showing Tumor Treating Fields with chemo abrogate cancer cell perforation. It led to a trial, the PANOVA-2 trial, that was run in Europe that showed efficacy for OS and PFS in patients with locally advanced pancreatic cancer, which included metastatic and locally advanced pancreatic cancer, more so in locally advanced that led to the PANOVA-3 trial, which was an international, global study. This was in more than 190 centers, 20 countries in Latin America, North America, Europe, and Asia. It was a randomized trial. Patients were randomized 1 to 1 to either chemotherapy with gemcitabine plus nab-paclitaxel per drug label. The other arm was with Tumor Treating Fields at 150 kHz for a recommendation for patients to wear it 18 hours per day. The primary end point of the trial was OS, overall survival. The secondary end point included other efficacy landmarks such as local PFS, pain control, quality of life, and safety. And there was a post hoc that looked at distant PFS. Dr. Shannon Westin: That's a pretty common secondary end point in pancreatic studies of looking at the pain-free interval. I thought that was really brilliant because, you know, I think in gyn cancers, we see resolution of symptoms as being a really big deal, but it's not necessarily something that we always look at. So I thought that was really nice that you included that. Okay, talk to us a little bit about the population. So, the population that actually got treated in PANOVA-3 is pretty generalizable to what people are treating in the clinic. Dr. Hani Babiker: So, in pancreatic cancer, unfortunately, most of our patients present, approximately 80%, with metastatic disease. Local is divided to resectable, borderline, and locally advanced. We studied this trial, a randomized trial, in locally advanced and unresectable, which is really an unmet need. Most of our patients with locally advanced and unresectable are grouped up with other trials in the metastatic setting without a focus on locally advanced and unresectable, save for a few trials. This year, a trial that we were looking for for a long time, the LAPLACE trial, unfortunately, that we were very excited about, this is a molecule that targeted connective tissue growth factor, that showed earlier efficacy in a randomized trial, did not meet up the median OS end point. And hence, PANOVA-3 is the first trial in locally advanced and unresectable that did meet its primary end point. So, it's a very unmet need in locally advanced and unresectable. A lot of the times, our patients in clinic are treated with frontline chemotherapy that was studied in metastatic disease and locally advanced and unresectable, which include either FOLFIRINOX, NALIRIFOX, or gemcitabine/abraxane. I do have in my clinic multiple patients that would stay on the regimen for such a long time, and then we would have to devise a mechanism of maintenance, although this is not studied really in details, either with capecitabine or dropping the oxaliplatin to continue FOLFIRI. And then we also approach chemoradiotherapy. So the trial was in a disease in pancreatic cancer that really is an unmet need. So the inclusion criteria included a patient with locally advanced and unresectable. These were done at multiple centers. Most of them academic centers were discussed at the tumor board, and if it's unresectable, they will be meeting specific metrics of appropriate liver function tests, kidney function tests, and blood counts. We excluded patients that obviously had, given that these are electric fields, patients that have, for example, stimulators or pacemakers, knowing that this could potentially affect some of these devices. But for the most part, it was locally advanced and unresectable patients with a very good performance status and good counts. Dr. Shannon Westin: That's great. I think everyone's excited to hear about the primary outcome of overall survival. What did you find, and how does it compare to some of the recent trials? Dr. Hani Babiker: We're very excited that it did meet its primary end point of median overall survival. It was very exciting knowing that a lot of us were disappointed a little bit of some of the trials that were presented at ASCO GI, such as the LAPLACE trial that I alluded to. Just before the presentation, the PRODIGE 29 trial that is in locally advanced and unresectable that randomized patients with locally advanced disease to either FOLFIRINOX or single-agent gemcitabine, allowing for a crossover, although it did meet its primary end point of PFS, there was no overall survival benefit. So that kind of got us a little bit disappointed, but having the PANOVA-3 trial being positive in median OS got us all excited. In addition, the 12-year overall survival rate was increased in both the intention-to-treat and modified intention-to-treat. The modified intention-to-treat were patients that have had at least one cycle of therapy with TTFields daily and/or one cycle with chemotherapy, which was gemcitabine plus nab-paclitaxel. There was a trend to improvement in PFS and local PFS, although that did not have statistical significance, but the 12-year PFS rate in both the intention-to-treat and modified intention-to-treat was significant. For me, as one of the investigators, that told me that there might be a specific biomarker that would tell me that patients could respond greater than others, more exceptional than others, given that 12-month PFS rate was improved. On a post hoc analysis, the distant PFS was improved with the intervention of Tumor Treating Fields with gemcitabine plus nab-paclitaxel. In addition, there was an improvement in global health status and quality of life in addition to pain-free survival, which is a strong hurdle in our patients with pancreatic adenocarcinoma that most present with significant abdominal pain. Dr. Shannon Westin: One of the other questions that I think has come up is around central review. So did you all use central review in this study? Dr. Hani Babiker: Most of the centers were academic centers. These were discussed in tumor boards, which included radiation oncologists and surgeons. I wanted to point out that it's very important to note that the primary end point was overall survival. So the primary end point was not PFS. Hence, the central review would help us, for example, with elaborating and making sure patients were actually locally advanced disease, but in a setting where the primary end point is overall survival, that was the key point of the clinical trial. This trial was discussed at academic centers, and all included tumor boards to decide if patients were locally advanced or not. In the trial, there was a good proportion of patients, or percentage, that had a CA 19-9 more than 1000. That could indicate that potentially there are a fraction of patients that actually had metastatic disease, micrometastatic disease. So that could hint towards why the median OS was slightly lower then in both arms when compared to, for example, the trial that was presented at ASCO GI, the LAPLACE trial. However, having said that, we were very excited about the trial. It was the first positive trial in locally advanced and unresectable to meet median OS survival. Dr. Shannon Westin: It's so awesome. So congratulations. Okay, so let's talk a little bit about your very detailed secondary end points because you had a lot of really prudent choices there. So anything that was interesting or informative in those end points? Dr. Hani Babiker: One major hurdle back we have for most of our patients with pancreatic adenocarcinoma, like I mentioned earlier, is pain. We try to approach it, obviously, with narcotics. If it doesn't work, we try to do celiac axis block interventionally, and that sometimes is successful and sometimes is not. So actually, to see the pain-free survival end point to be met was very exciting for us. And as for me, as a scientist that studies TTFields in clinic and lab as also to develop a mechanism and understanding really how that works. That was very important for us that in addition to chemotherapy, it improved pain-free survival or deterioration of pain. And most importantly, our patients with pancreatic cancer, this disease is very aggressive. It affects quality of life of patients. Patients feel fatigued, tired. It's a procoagulant tumor that causes clots and strokes, etcetera, marantic endocarditis. And one big problem we deal with when we're seeing patients in clinic is obviously that quality of life. Although data have shown with treatment, with frontline regimens, that quality of life improves with treatment and chemotherapy, it's actually great to see that that improvement happens early in addition to Tumor Treating Fields. The other interesting point was that it was not only pain and quality of life, but also digestive symptoms that are improved with this intervention, knowing that a lot of our patients do have pancreatic cancer, pancreatic exocrine insufficiency that affect also with digestion, and a lot of our patients have abdominal pain after eating and diarrhea. So it was interesting to see that also improved with the intervention. Dr. Shannon Westin: You have touched a little bit on some of the adverse events, kind of with the TT mechanisms, but I'd love to hear a little bit more detail around adverse events in general in this study, as well as specific AEs related to the Tumor Treating Fields. Dr. Hani Babiker: Absolutely. So when we compared both arms, there was a similar toxicity related to the regimen, mostly with chemotherapy, but in specifically to Tumor Treating Fields, there was a rash, and that included dermatitis and rash. Most of the side effects were grade 1 and grade 2. Grade 3 toxicities related to skin was less than 10%, approximately 7% to 8%, and hence did not affect many patients. But it was something to note, and it's something that in the future, when we develop a mechanism of treating patients to note early. We in our clinic have learned to treat patients in the clinical trial early with topical steroids to each patient, of shifting the arrays to mitigate some toxicity and rash. We do advise our patients in hot areas, we keep them aware that sweating, for example, can lead to higher conductivity of electrical fields with a predisposition for rash. So if there's an opportunity to stay in a little bit of a cold area, make sure that the arrays are shifted, use topical steroids early. If it's a significant rash, to hold treatment for at least 48 hours and speak to the investigators. And through these mechanisms, we have learned that we were able to mitigate the rash quite a bit. Dr. Shannon Westin: That's awesome. Thank you so much. Yeah, I'm, it's summer right now, and I think- I'm in Texas, you're in Florida, like we know. Okay, so I guess, again, you have been kind of touching on this, but I would love to know, like if in the quality-of-life assessments or if just in your discussions with patients, like how easy is this to use? How easy is the Tumor Treating Fields device to use, and what do patients really think? Dr. Hani Babiker: Absolutely. We have learned that whenever we speak with patients, it's always good to discuss with them briefly the science of it. A lot of patients would want to know if it's interventional, is that something that goes, is delivered percutaneously or not, and we explain that these are delivered through arrays that are through the skin. We always touch base with them about a lot of question I get about mechanism of action and then about compliance. So I think one important thing to note is that compliance with the use of the device is a lot of the question we'll get quite a bit. Patients know there's going to take an effort from them, and some of my patients enjoyed it because they felt like they also are fighting the disease by wearing the device. I have learned very quickly that having a team, surrounded by a team that knew how to mitigate some of the side effects and knew how to explain how to use the device helped quite a bit. And this included some of our nurses and our nurse practitioners and our clinical research coordinators who've done a wonderful job of showing these arrays actually to patients before they start on the trial, look at it, know how it works. The other point to know is that the sponsor provided Device Support Specialist, we call them DSS, they have been instrumental in helping us, helping the patients know how to use the device, how to use the generator, how to change the batteries, and that helped us conduct the trials and enroll very well. I would envision in the future with education and relying on the Device Support Specialist and having a team that knows how to use the device and mitigate some of the side effects will go a long way for patients to learn about this treatment. Many of the times our patients said while they are on the clinical trial felt like they are also being part of this team in applying the device and fighting the cancer. Dr. Shannon Westin: That's awesome. Well, I guess the bottom line. Is it ready for prime time? Is this something you are going to use for your patients in the clinic? Dr. Hani Babiker: Absolutely. In a disease that has poor prognosis, and we are trying our best to find new treatments to fight this cancer and treatment modalities, presenting patients with all the treatment options that are out there would be recommended. It's what I would do it for in my clinic. And you know, it's funny that I am mentioning that right now. I had a patient who was seen internationally asking about the trial and the device and had locally advanced and unresectable before they start frontline treatment. I do think that there is going to be an educational piece. Obviously, this is not a pill, it's not an intravenous chemotherapy that we're very well and accustomed to. And some of us in academic centers know it very well. I usually joke that whenever I am talking about it in pancreatic cancer, if there is a radiation oncologist in the room, they will be like, "Yeah, we know all about it. We have been treating patients with GBM over there." So a lot of the times, when we first went to trial, if I had any questions, I would call them and ask them. So from their perspective, they, because they use it as a standard of care in treatment of GBM, they develop significant expertise in it. I think in the GI world, specifically and with oncologists that treat pancreatic cancer and specifically oncologists in the community, learning about the device and how to use it, how to recommend it, how to mitigate side effects, will be hopefully for prime time in the future. Dr. Shannon Westin: That's great. Sounds like some real educational opportunities there. Well, this has been awesome. Thank you so much, Dr. Babiker. I mean, I learned a ton, and I wish that we could find a way to use this in gynecologic cancers, but really, really just want to commend you on the design of the trial and the success in this really devastating disease. So again, this was "Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: A Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study." And as always, I am your host, Shannon Westin. Please go check out our other offerings wherever you get your podcasts and have an awesome day. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Dr. Babiker Disclosures Consulting or Advisory Role: Endocyte, Celgene, Idera, Myovant Sciences, Novocure, Ipsen, Caris MPI, Incyte, Guardant Health Speakers' Bureau: Guardant Health Research Funding:  Spirita Oncology, Novocure, AstraZeneca, JSI, Incyte, Qurient, HiFiBiO Therapeutics, Revolution Health Care, Elevation Oncology, Dragonfly Therapeutics, Zelbio, BMS, Mirati Therapeutics, Strategia        

Overview of the prophecy of Habakkuk, one of the minor prophets in the Old Testament. #MinorProphets #sermon #preaching #Habakkuk #LordssecondAnswer #judgment #Babylonians #evil #judge #Babylon #unpunished #judgmentseatofChrist #Psalm115v2 #Daniel5 #Habakkuk2 #2Corinthians5v10 Bill James takes us through the incommunicable attributes of God, the characteristics in which God differs from us. #doctrine #summaryofBible #attributesofGod #incommunicable #cold #distant #rigid #impassibilityofGod #unemotional #impassable #constant #consistent #compassionate #gracious #wise #just #holy #wrath #evil #Psalm7v11 #1John1v9 For more audio from GBM, visit gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Gabe is back with a brand new Gabe's Big Move to talk about the evolution of #Survivor juries and what it means to be a juror!Subscribe to the Reality Aftershow and follow Gabe on socials @gabeortisCheck out the ALL NEW RealityAfterShow.com official website!Join Jonny LIVE SurvivorTix.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/reality-after-show--5448874/support.

Overview of the prophecy of Habakkuk, one of the minor prophets in the Old Testament. #MinorProphets #sermon #preaching #Habakkuk #LordsAnswer #judgment #Babylonians #superpower #godless #evilnation #patience #trust #Habakkuk1v5-2v1 Bill James takes us through the incommunicable attributes of God, the characteristics in which God differs from us. #doctrine #summaryofBible #attributesofGod #incommunicable #omnipotent #Moses #burningbush #IAM #eternal #Godstiming #unchanging #immutable #Exodus3v14 #Psalm33v11 #Psalm90v4 #Psalm119v89 #Isaiah46v9-10 #Jeremiah31v3 #Galatians4v4-5 #James1v17 For more audio from GBM, visit gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

TCH is a ministry of Gospel Broadcasting Mission.GBM's mission is to broadcast the message of Jesus, in their own language, to unreached people groups and tribes world-wide.One of the most amazing things God has done for us is, He sent his son to live among us. We learn of God as we learn of Jesus, and we learn from Jesus through his teaching, his miracles, but, maybe, most of all, through His conversations with people. In many Bibles, the quoted words of Jesus are printed in Red, and this month Aaron Brockett has been sharing from the Bible's book of John a series of messages entitled Red Letter Talks. Aaron Brockett is a preaching minister at Trader's Point Christian Church with multiple campuses in Indianapolis, IN. It's only 10 verses, only 2 paragraphs, yet in every conversation, every teaching moment Jesus is a master at painting a portrait of God's intended kingdom for us, whom He loves. In today's message Jesus draws upon the simple vocation of shepherding to unpack the depth of relationship He wants to have with us. Here's Aaron to unravel one deep conversation… To support this ministry financially, visit: https://www.oneplace.com/donate/326/29

¿Por qué Pioneros es el evento líder de asesoría financiera en México? En entrevista con El Economista, Luis Madrigal, director de GBM Advisors, nos contó detalles de la tercera edición de este foro: desde su creación, participantes, propuesta de valor y el papel de GBM para impulsar el emprendimiento y la profesionalización de “la carrera del futuro”. ¡Conoce toda la información!    #Pioneros2025 #AsesoríaFinanciera #GBM #GBMAdvisors

Overview of the prophecy of Habakkuk, one of the minor prophets in the Old Testament. #MinorProphets #sermon #preaching #Habakkukcomplaint #Godsname #Godsglory #kingJosiah #ungodliness #unrighteousness #sadness #Habakkuk1v1-4 Bill James takes us through the incommunicable attributes of God, the characteristics in which God differs from us. #doctrine #summaryofBible #attributesofGod #incommunicable #omnipotent #suffering #wickedprosper #omniscient #omnipresent #Genesis1v1 #Psalm16:11 #Psalm33 #Psalm139 #Proverbs15v29 #Jeremiah23v23-24 #Daniel4v35 #Matthew6v26 #Acts17v26-28 #Colossians1v17 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Check out this week's QuadCast as we highlight how intranasal mupirocin decreases radiation dermatitis associate with nasopharynx radiation, the lack of benefit of immunotherapy in MGMT-unmethylated GBM, the role of neoadjuvant chemoradiation in unresectable pancreatic cancer, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Overview of the prophecy of Habakkuk, one of the minor prophets in the Old Testament. #MinorProphets #ProphecyofNahum #sermon #preaching #Habakkuk #Babylon #Judah #violence #injustice #prosperityofthewicked #judgment #CyrusthePersian #Darius #sovereigntyofGod #Psalm73 #Daniel5v30-31 #Habakkuk Bill James takes us through the incommunicable attributes of God, the characteristics in which God differs from us. #doctrine #summaryofBible #attributesofGod #incommunicable #Moses #burningbush #IAm #eternal #uncreated #IndependenceofGod #complete #Exodus3v13-14 #Exodus3v16-17 #Acts17v25 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Grief is not one-size-fits-all. In this episode of The Patient From Hell, grief coach Holly Gainsboro breaks down anticipatory grief after a cancer diagnosis (incl. glioblastoma/GBM), the harm of “be strong,” and simple daily practices that actually help patients, caregivers, and clinicians. We cover how to talk to kids after diagnosis, caregiver exhaustion, why grief isn't linear, and what to ask when seeking a therapist with real grief training.About Our Guest: Holly Gainsboro, founder of Golden Heart Grief Support & Education, is a Grief Coach/Support Specialist & Grief Educator. Holly's late husband, Steven, died in December 2010, from glioblastoma. Holly began her work in the grief field more than a decade ago, earning her first certification as a Grief Recovery Specialist. She continued her studies and received her certification as a Grief Educator with world renowned grief expert, David Kessler, as well as being certified as a Grief Support Specialist from the University of Wisconsin. Holly believes that learning never stops and recently completed another training and certification as a Grief & Loss Provider with Claire Bidwell Smith. Holly recognizes that grievers don't need to be fixed, they need to be heard, seen, and supported. Holly's passion/purpose is to be present for those who have experienced losses by guiding them through the feelings of grief and leading them to a place of peace and hope while honoring their relationships/experiences. Holly says," I normalize grief and invite growth and learning throughout the journey using a heart centered, and holistic approach.”Holly works 1:1 with women who have lost a loved one to a brain tumor or are caring for a loved one diagnosed with a brain tumor, facilitates grief support groups, and leads grief education workshops for various organizations. She is the co-host of the podcast Creating Space for Grief & Hope. What you'll learn:What anticipatory grief is (and why it's not just anticipating death)How to support a spouse/partner & children after a GBM diagnosisThe difference between platitudes and evidence-informed supportPractical tools: movement, journaling, nature, hydration, restWhy feeling your feelings = real strengthConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @MantaCares and visit our website at MantaCares.com for more episodes and updates. Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.Tags:grief, anticipatory grief, glioblastoma, GBM, brain tumor, cancer caregiving, caregiver support, oncology, oncology support, patient advocacy, grief coach, grief educator, grief myths, grief practices, palliative care, bereavement, grief tools, cancer diagnosis, mental health in medicine, The Patient From Hell, Manta Cares

The last of the Bible talks given at the 2025 Athelington summer camp run by Grace Baptist Mission These talks are from the book of Judges and the speaker is James Hammond, a GBM missionary serving in Bordeaux, France. #GraceBaptistMission #Judges13-16 #Samson #Athelington2025

The fourth Bible talk given at the 2025 Athelington summer camp run by Grace Baptist Mission These talks are from the book of Judges and the speaker is James Hammond, a GBM missionary serving in Bordeaux, France. #GraceBaptistMission #Judges10v6-11v40  #Jephthah #Athelington2025

A series that examines the principles of work and finance using the prayer ‘Give us today our daily bread' as its starting point. #Money #finance #work #dailybread #Saving #sharing #spending #debt #giving #provision #expenditure #Proverbs3v9-10 #Proverbs21v20 #Proverbs30v25 #Malachi3v8-10 #1Corinthians10v31 In this series a pastor is talking to his people about different issues that many of them face. #Pastoral #Tough #Wiseliving #James1v5  For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Welcome to the Christian's Hour Program! TCH is a ministry of Gospel Broadcasting Mission. GBM's mission is to broadcast the message of Jesus, in their own language, to unreached people groups and tribes world-wide. We learn a lot about each other in our conversations. And some conversations touch us more deeply than others. One of the most amazing things God has done for us, is in sending his son to live among us. We learn of God as we learn of Jesus, and we learn from Jesus through his teaching, and also, people's conversations with Him, recorded in the Bible. In many Bibles, the quoted words of Jesus are printed in Red, and this month Aaron Brockett is sharing from the Bible's book of John a series of messages simply entitled Red Letter Talks. Aaron Brockett is the preaching minister at Trader's Point Christian Church with multiple campuses in Indianapolis, IN. So, at a town well, Jesus has a conversation with a woman, steming from a request for a drink of water. Uneventful, “insignificant”, right? Well, everything about that conversation, even the fact that it took place, is more than chance. In today's message Aaron unpacks what he calls “one of the most significant conversations Jesus ever had.” Here's Aaron… To support this ministry financially, visit: https://www.oneplace.com/donate/326/29

The third Bible Talk given at the 2025 Athelington summer camp run by Grace Baptist Mission These talks are from the book of Judges and the speaker is James Hammond, a GBM missionary serving in Bordeaux, France. #GraceBaptistMission #Judges7v1-25 #Gideon #Athelington2025

The second Bible talk given at the 2025 Athelington summer camp run by Grace Baptist Mission These talks are from the book of Judges - the speaker is James Hammond, a GBM missionary serving in Bordeaux, France. #GraceBaptistMission #Judges4v1-5v31 #Deborah #Athelington2025

The first of the Bible Talks given at the 2025 Athelington summer camp run by Grace Baptist Mission These talks are from the book of Judges - the speaker is James Hammond, a GBM missionary serving in Bordeaux, France. #GraceBaptistMission #Judges2v16-25,3v12-25 #Ehud #Athelington2025

A series that examines the principles of work and finance using the prayer ‘Give us today our daily bread' as its starting point. #Money #finance #work #dailybread #Giving #tithing #devotion #worship #commitment #trust #Deuteronomy16v17 #1Chronicles29 #Acts11v29 #Acts20v35 #1Corinthians16v1-4 #2Corinthians8v9-12 In this series a pastor is talking to his people about different issues that many of them face. #Pastoral #Tough #difficulttimes #problems #suffering #Psalm46 For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

A series that examines the principles of work and finance using the prayer ‘Give us today our daily bread' as its starting point. #Money #finance #work #dailybread #planning #providing #Proverbs6v7-8 #Proverbs11v15 #Proverbs21v20 #Proverbs22v7 #Proverbs22v26-27 #Proverbs24v27 #Proverbs27v23-27 #Romans13v7-8  In this series a pastor is talking to his people about different issues that many of them face. #Pastoral #Faith #faithfulness #trust #trusting For more audio from GBM, visit www.gbm.org.uk/listen To contact us, please email servingtoday@gbm.org.uk

Reinventar la industria financiera desde adentroEn este episodio, Pedro de Garay, CEO de GBM+, nos comparte su visión sobre cómo transformar una empresa tradicional en una plataforma digital que empodera a miles de inversionistas.También hablamos de su rol como cofundador de Siclo y sus restaurantes, y de cómo aplica la misma filosofía de liderazgo y propósito sin importar la industria.Una conversación honesta sobre riesgos, crecimiento y el futuro del dinero, el bienestar y la hospitalidad en LATAM.

Check out this week's QuadCast as we highlight a PSMA Theranostic contender, new guidelines (and name) for GBM, current management limitations in NSCLC, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Samira and guest Chris Schuler delve into the emotional and practical challenges faced during the cancer diagnosis and treatment process. Chris shares his personal experiences as a caregiver for his father diagnosed with glioblastoma, highlighting the confusion and fear that accompany such news. The conversation explores the importance of understanding treatment options, the role of family in caregiving, and the complex emotions of grief that arise during this journey. Chris emphasizes the need for clear communication and advocacy in healthcare, as well as the disconnect between the information provided and the emotional realities faced by families. About our Guest:Chris is a staunch brain cancer awareness advocate. He was the primary caregiver to his late Dad, Donald Schuler, who was diagnosed with GBM in July 2021. He works closely with organizations across the globe, amplifying their critical work and building key relationships to further improve outcomes for patients.His career has spanned almost two decades through philanthropic roles in a variety of industries including non-profit, public and private higher education, and healthcare. He's currently working with Cure Brain Cancer Foundation, an Australian non-profit dedicated to improving outcomes in brain cancer. He's a Venture Partner with Varia Ventures, working to raise awareness for emerging venture funds dedicated to uncovering and funding innovative discoveries to improve brain health. He also works closely with SageMedic, a precision oncology start-up supporting patients looking for the most effective treatment for cancer. TakeawaysChris felt a sense of responsibility to support his parents after the diagnosis.The emotional impact of a terminal diagnosis can be overwhelming.Understanding treatment options is crucial for caregivers.Grief can manifest differently in family members during a health crisis.Clear communication from healthcare providers is essential.Many caregivers feel lost in the healthcare system.The binder provided by the hospital was not helpful for Chris or his mom.Caregiving involves navigating complex emotions and responsibilities.Patients and families need to advocate for themselves in medical settings.The experience of receiving a terminal diagnosis is traumatic and disorienting. The feeling of helplessness is a common struggle for caregivers.Chris's mother chose not to Google her husband's condition, living in the moment instead.Chris believes there are hidden joys in caregiving, despite the challenges.Chapters00:00 Introduction and Context of Caregiving02:54 Navigating the Diagnosis Process05:54 The Emotional Impact of a Terminal Diagnosis08:50 Understanding Treatment Options and Next Steps11:53 The Role of Family in Caregiving15:07 Grief and Its Manifestations in Caregiving17:56 The Disconnect Between Information and Understanding25:00 Navigating Cancer: A Personal Journey31:48 The Search for Answers: Clinical Trials and Second Opinions39:51 The Emotional Toll: Grief, Faith, and Resilience46:49 The Caregiver's Perspective: Finding Joy Amidst SorrowConnect with Us:Enjoyed this episode? Make sure to subscribe, rate, and review! Follow us on Instagram, Facebook, or Linkedin @MantaCares and visit our website at MantaCares.com for more episodes and updates. Disclaimer:All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

Granulomatosis with Polyangiitis (GPA) – Recognition and Management in the ED Hosts: Phoebe Draper, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/GPA.mp3 Download Leave a Comment Tags: Rheumatology Show Notes Background A vasculitis affecting small blood vessels causing inflammation and necrosis Affects upper respiratory tract (sinusitis, otitis media, saddle nose deformity), lungs (nodules, alveolar hemorrhage), and kidneys (rapidly progressive glomerulonephritis) Can lead to multi-organ failure, pulmonary hemorrhage, renal failure Red Flag Symptoms: Chronic sinus symptoms Hemoptysis (especially bright red blood) New pulmonary complaints Renal dysfunction Constitutional symptoms (fatigue, weight loss, fever) Workup in the ED: CBC, CMP for anemia and AKI Urinalysis with microscopy (hematuria, RBC casts) Chest imaging (CXR or CT for nodules, cavitary lesions) ANCA testing (not immediately available but important diagnostically) Management: Stable patients: Outpatient workup, urgent rheumatology consult, prednisone 1 mg/kg/day Unstable patients: High-dose IV steroids (methylprednisolone 1 g daily x3 days), consider plasma exchange, cyclophosphamide or rituximab initiation, ICU admission Conditions that Mimic GPA: Goodpasture syndrome (anti-GBM antibodies) TB, fungal infections Lung malignancy Other vasculitides (EGPA, MPA, lupus)

#Podcast #MéxicoVsGoogle #TrumpMobile #aibipocketEn este episodio te contamos todo sobre la demanda del gobierno mexicano contra Google, y el caso en Puebla donde una persona podría ir a la cárcel por insultos en redes. Además, Trump anuncia su propio celular: Trump Mobile. También conocimos el Aibi Pocket, un gadget estilo Tamagotchi pero potenciado con inteligencia artificial, y unos lentes que integran pantalla. Cerramos con entrevista a GBM, el supuesto “WhatsApp de Twitter” y nuestra opinión sobre la película de F1 que ya vimos.

Bobby Dutton | Founder ,GBM 6  Bobby Dutton, an entrepreneur and philanthropist who has pioneered innovative event design and operational strategies in the live events industry. His concept of "pilot thinking" offers a unique approach to achieving happiness and efficiency.Bobby, being a licensed commercial pilot, brings a fresh perspective that could intrigue your audience. He can provide actionable insights on leadership and success by drawing parallels from both the aviation and event management sectors.His work has impacted 2.5M+ people across 47 states and counting. He love helping organizations, colleges, and businesses create experiences that energize, inspire, and drive results.He  also help teams and leaders work smarter, move faster, and thrive under pressure. Whether it's time management, team efficiency, or building a culture of creativity, He bring insights from event production, engineering, music, and even aviation.  

This week on Gabe's Big Move Gabe answer the question, how has COVID and bingewatching changed the way contestants play #Survivor? Plus the first guest in the history of GBM joins the show! All that and more tonight on Gabe's Big Move brought to you by the Reality Aftershow 

In this episode of Bench to Bedside, Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center, sits down with Dr. David Akhavan, a physician-scientist pioneering cell therapy research for brain cancer. Dr. Akhavan discusses the revolutionary potential of chimeric antigen receptor (CAR) T-cell therapy in treating cancers like glioblastoma, the complexities involved and the innovative approaches his team is employing, such as smarter engineered T-cells and nanoparticles. Highlighting the collaboration within KU Cancer Center, Dr. Akhavan also shares personal insights into his motivation and the future of cancer treatment. Do you have questions about cancer? Call our Bench to Bedside Hotline at (913) 588-3880 or email us at benchtobedside@kumc.edu, and your comment or question may be shared on an upcoming episode! If you appreciated this episode, please share, rate, subscribe and leave a review. To ensure you get our latest updates, For the latest updates, follow us on the social media channel of your choice by searching for KU Cancer Center. Links from this Episode: Learn more about cell therapy at KU Cancer Center Learn more about brain cancer Read more about Dr. Akhavan's work on the KU Cancer Center blog, “Exploring Immunotherapy Treatments to Treat Brain Cancer” Learn about Head for the Cure Read how physician-scientists at KU Cancer Center bridge the gap between the laboratory and the clinic  

Researchers at Brown University have developed a combination treatment that significantly increases survival in mice with glioblastoma (GBM), a highly aggressive and treatment-resistant brain cancer. The approach uses a new class of drugs called imipridones along with radiation therapy and standard chemotherapy. This triple therapy, known as IRT, was recently detailed in a study published in Oncotarget. Understanding Glioblastoma and the Need for Better Therapies Glioblastoma is the most common and aggressive malignant brain tumor in adults. It grows quickly and is difficult to treat, often leading to poor outcomes. Most patients survive less than 15 months after diagnosis, even when treated with surgery, radiation, and the chemotherapy drug temozolomide (TMZ). This treatment may slow the disease, but it does not typically stop it. Full blog - https://www.oncotarget.org/2025/06/04/experimental-triple-therapy-improves-survival-in-glioblastoma-mouse-model/ Paper DOI - https://doi.org/10.18632/oncotarget.28707 Correspondence to - Wafik S. El-Deiry - wafik@brown.edu Video short - https://www.youtube.com/watch?v=Q_mXy8mana0 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28707 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, glioblastoma multiforme, IDH, ONC201, ONC206, MGMT, temozolomide, radiotherapy To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

En este episodio desde el North Capital Forum, me senté con Pedro de Garay, director general de GBM. Hablamos de cómo invierte el mexicano, qué errores comete al comenzar y qué tendencias están captando más lana hoy en día. También platicamos sobre inteligencia artificial, nearshoring, behavioral finance y cómo aprovechar mejor tu dinero a largo plazo. Una mirada honesta, directa y con datos reales sobre cómo se mueve el dinero en México.

Dr. John Sweetenham shares highlights from Day 2 of the 2025 ASCO Annual Meeting, including new data on the treatment of ER+/HER2-negative breast cancer and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high risk of recurrence.  Transcript Dr. John Sweetenham: Hello, I'm Dr. John Sweetenham, your host of the ASCO Daily News Podcast, welcoming you to our special coverage of the 2025 ASCO Annual Meeting. Today, I'll be bringing you my takeaways on selected abstracts from Day 2 of the Meeting. My disclosures are available in the transcript of this episode.  Today's selection features important, new data on the treatment of ER-positive, HER2-negative breast cancer, the use of tumor treating fields in combination with chemotherapy for locally advanced pancreatic cancer, and potentially practice-changing results for patients with cutaneous squamous cell carcinoma at high-risk of recurrence.  Our first selected abstract is LBA1000. This important phase 3 study was presented by Dr. Erika Hamilton from the Sarah Cannon Research Institute in Nashville and evaluated the use of a novel agent, vepdegestrant, in patients with ER-positive/HER2-negative breast cancer, which had progressed after first-line endocrine therapy. Vepdegestrant is a selective oral PROTAC estrogen receptor degrader, which targets wild-type and mutant estrogen receptor through a novel mechanism of action which directly harnesses the ubiquitin-proteasome system to degrade ER. It has potential advantages over fulvestrant, a selective ER degrader which has to be administered intramuscularly and has limited benefit in patients who progress after endocrine therapy plus a CDK4/6 inhibitor.  Building on the encouraging results from the initial phase 1/2 study of vepdegestrant, Dr. Hamilton reported results from the VERITAC-2 global phase 3 trial, comparing this agent with fulvestrant. The patients in the study had already received treatment with hormone therapy and a CDK inhibitor and were randomly assigned to receive treatment with either vepdegestrant (313 patients) or fulvestrant (311 patients). The vepdegestrant was taken orally each day, while the fulvestrant was given intramuscularly on days 1 and 15 of the first cycle of treatment and day 1 of each subsequent treatment cycle. Patients were stratified by the presence of wild-type ER or ESR1 mutation. A total of 43.3% of patients had ESR1 mutations; 136 of those were in the vepdegestrant group and 134 in the fulvestrant group.   For patients with ESR1 mutations, vepdegestrant significantly increased progression-free survival compared with fulvestrant. For patients who received vepdegestrant, the median PFS was 5 months versus 2.1 months for those who received fulvestrant. The clinical benefit rate was 42.1% in the vepdegestrant group vs. 20.2% in the fulvestrant group. The overall response rate was 18.6% in the vepdegestrant group compared with only 4% in the fulvestrant group.  The PFS and response benefits of vepdegestrant were largely restricted to the population with ESR1 mutations. Overall survival data are currently immature. The safety profile was favorable, with fewer than 5% of patients having dose reductions or discontinuation due to toxicity. The most frequent toxicities were fatigue, nausea, and elevated transaminases.  The authors concluded that oral vepdegestrant demonstrates statistically significant and clinically meaningful improvement in progression-free survival compared with fulvestrant in this group of patients with ESR1-mutated ER+/HER2- advanced breast cancer who have progressed after endocrine therapy and a CDK inhibitor. Patients with recurrent disease in this context are now routinely tested for ESR1 mutations, and this agent is for sure a potential treatment option for them.  The next study on today's episode, LBA4005, reports on the use of tumor treatment fields for patients with locally advanced pancreatic cancer. Tumor treatment fields are electric fields which disrupt cell division and may also induce an enhanced immune response, using a non-invasive portable device attached to the skin, and are already approved for the treatment of some cancers, including GBM and non-small cell lung cancer. A previous phase 2 trial, PANOVA-2, confirmed the feasibility and safety of using this approach in combination with gemcitabine plus or minus nabpaclitaxel in pancreatic cancer. In today's presentation, Dr. Vincent Picozzi from the Virginia Mason Medical Center in Seattle presented the results of the PANOVA-3 trial, a phase 3 study comparing gemcitabine and nabpaclitaxel with the same chemotherapy plus tumor treatment fields in patients with locally advanced pancreatic adenocarcinoma.  Five hundred and seventy-one eligible patients were enrolled in the study with a total of 405 (198 in the treatment field group and 207 in the standard arm) comprising the modified intent- to-treat population. The duration of chemotherapy treatment was comparable in both study arms, and patients receiving treatment fields had a median exposure of almost 27 weeks.  Statistically significant improvements were observed for several study endpoints, including overall survival (a median of 16.2 versus 14.2 months), distant PFS (at 13.9 versus 11.5 months) and pain-free survival (at 15.2 versus 9.1 months), all in favor of the treatment fields arm. Although quality of life data were not reported in detail, the authors noted a significant improvement in global health status in the treatment fields arm. Safety data showed a higher level of skin adverse events in the treatment fields arm but were otherwise as expected for the GnP combination.  These are quite remarkable results which add to the growing evidence base for tumor treatment fields and are particularly compelling in this patient group given the substantial improvement in pain-free survival. It will be especially interesting to see the mature analysis of the quality-of-life endpoints in a subsequent report.  The final selection today is Abstract 6001, which describes the C-POST trial, a phase 3 trial of adjuvant cemiplimab versus placebo in patients with high-risk cutaneous squamous cell carcinoma of the skin. This study was presented by Dr. Danny Rischin from the Peter MacCallum Cancer Centre in Melbourne, Australia.   Although surgical resection with or without adjuvant radiation is curative in 90% of patients with cutaneous squamous cell carcinoma, high-risk features, including nodal disease, skin and subcutaneous metastases, perineural invasion and bone involvement, predict for an inferior prognosis.  Cemiplimab, a PD-1 targeting antibody is standard therapy for patients with locally advanced or metastatic disease who are not candidates for curative surgical resection or radiation therapy, with an overall response rate of almost 50%.  The C-POST study evaluated the use of cemiplimab as adjuvant therapy following surgery and radiation in high-risk patients, compared with placebo. Treatment was administered at 3-week intervals for 12 weeks, and then 6-week intervals for a further 36 weeks, with a primary endpoint of disease-free survival. Four hundred and fifteen patients were randomized in the study, 209 to cemiplimab and 206 to placebo. With median follow-up at 24 months, Dr. Rischin reported a highly significant improvement in disease-free survival for the cemiplimab arm, 49.4 months for placebo versus not reached for cemiplimab, with improvements also observed in the rates of locoregional recurrence and distant recurrence at 80% and 60% reductions, respectively. No new safety signals were observed.  This study is potentially practice-changing and provides strong evidence that cemiplimab should be considered the new standard of care in this clinical context.  Thanks for listening today and join me again tomorrow to hear more top takeaways from ASCO25. If you value the insights that you hear on the ASCO Daily News Podcast, please remember to rate, review, and subscribe wherever you get your podcasts.  Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speaker:   Dr. John Sweetenham   Follow ASCO on social media:    @ASCO on Twitter   @ASCO on Bluesky   ASCO on Facebook   ASCO on LinkedIn    Disclosures:   Dr. John Sweetenham:   No relationships to disclose  

'DAVE ALLEN v DEONTAY WILDER...' - ADAM SMITH HONEST! / FURY v JOSHUA, PACQUIAO, GBM, FISHER, TAYLOR Learn more about your ad choices. Visit megaphone.fm/adchoices

Scientists have engineered small, targeted proteins that can penetrate brain cancer cells and prevent them from invading healthy tissue, offering a promising new approach to treating glioblastoma multiforme (GBM), one of the deadliest forms of brain cancer. This strategy was developed by researchers at the University of Nevada, Reno, and published recently in Oncotarget. The Challenge of Treating Glioblastoma Multiforme Glioblastoma is an aggressive and fast-growing brain tumor that infiltrates healthy brain tissue, making complete surgical removal nearly impossible. Standard treatments like chemotherapy and radiation can slow its growth but rarely prevent it from returning. One major reason for this invasiveness is a group of enzymes known as matrix metalloproteinases (MMPs), which break down surrounding tissue to allow cancer cells to spread. Among these, MMP-9 plays a particularly important role in driving tumor progression and resisting existing therapies. Attempts to block MMPs using small-molecule drugs have failed in clinical trials due to problems like poor selectivity and harmful side effects. Researchers have been searching for safer, more targeted methods to interfere with these enzymes and limit glioblastoma's spread. The Study: Engineered Proteins to Inhibit Tumor Invasion In the study called “Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells,” researchers Elham Taheri and Maryam Raeeszadeh-Sarmazdeh investigated tissue inhibitors of metalloproteinases (TIMPs), which are natural blockers of MMPs, and their engineered modified versions made to work better. Specifically, the team studied TIMP-1, TIMP-3, along with two engineered molecules, mTC1 and mTC3, in laboratory cell models of GBM. Full blog - https://www.oncotarget.org/2025/05/21/engineered-proteins-show-promise-in-stopping-glioblastoma-invasion/ Paper DOI - https://doi.org/10.18632/oncotarget.28691 Correspondence to - Maryam Raeeszadeh-Sarmazdeh - maryamr@unr.edu Video short - https://www.youtube.com/watch?v=tdBlkOX50D8 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28691 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, TIMP minimal variants, glioblastoma multiforme (GBM), brain cancer, MMP inhibitors To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

En este nuevo episodio de la sexta temporada de Análisis BIVA nos acompaña Miriam Acuña, Economista en Jefe de GBM, quien nos habla sobre la última decisión en materia de política monetaria por parte de Banxico, en qué consiste el nuevo acuerdo comercial entre EE.UU. y China, y la posible imposición de impuesto del 5% a las remesas. Conducido por Salvador Leal, Director de Comunicación de BIVA.

Season 4 of Glioblastoma aka GBM kicks off Brain Tumor Awareness Month with a closer look at CeGaT, a genetic diagnostics company based in Tübingen, Germany. Founded in 2009 by Dr. Saskia Biskup and Dirk Biskup, CeGaT focuses on identifying rare diseases and tumor-specific mutations through advanced sequencing technologies. In this episode, we speak with Dr. Biskup and Florian Battke, Head of Research & Development, about what genetic sequencing is, how it's used in the context of brain tumors, and what they see as the next frontier for diagnosing and treating diseases like glioblastoma. We discuss how long-read sequencing may offer greater accuracy in identifying genetic changes and what that could mean for patients navigating difficult diagnoses. This episode explores the broader role that genomics can play in brain cancer research and the questions still left to answer as science continues to evolve. To learn more about the work CeGaT is doing, visit them online at https://cegat.com/ This episode is intended for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance specific to your health or treatment plan.

In episode 87 of the Summits Podcast, co-hosts Vince Todd, Jr. and Daniel Abdallah are joined by Scott Kennedy, Director of Operations at Four Day Ray Brewing and Team Heroes athlete. Tune in for a peek inside the Indiana-based brewery and how the Team Heroes family supports each other, both on the bike and off. For more on Four Day Ray Brewing, visit fourdayray.com.

“Everyone's brain is extremely heterogenic, so it's different. You can put five of us in a room; we can all have the same diagnosis of a [glioblastoma multiforme], but all of ours can be different. They're highly aggressive biologically. It's a small area in a hard shell. So trying to get through the blood–brain barrier is different. There's a lot of areas of hypoxia in the brain. There's a lot of pressure there. The microbiology is very different—it's a cold environment versus a hot environment—and then the pathways are just different,” Lori Cappello, MSN, APN-C, CCRP, research advanced practice nurse at the John Theurer Cancer Center of Hackensack Meridian Health in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about brain malignancies and caring for patients with them. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 25, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to brain malignancies and their diagnosis and treatment. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 235: Self-Advocacy Skills for Patients Episode 166: Cognitive Behavioral Interventions Help Patients With a Spectrum of Cancer Symptoms ONS Voice articles: Glioblastoma Diagnosis, Treatment, Side Effect Management, and Survivorship Recommendations Blocking Fatty Acid Storage May Induce Glioblastoma Apoptosis Brain Tumor Navigator Role Bridges the Intersection of Cancer and Neuroscience Researchers Tie More Cancers, Mortality to NF1 Disorders Larotrectinib and Other Tumor-Agnostic Targeted Therapies Are Leading Cancer Care Into the Next Frontier McCain Announcement Sheds Light on Nurses' Role in Advance Care Planning ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) Clinical Journal of Oncology Nursing articles: Implementing a Standardized Educational Tool for Patients With Brain Tumors Undergoing Concurrent Temozolomide and Radiation Therapy Exercise Intervention: A Pilot Study to Assess the Feasibility and Impact on Cancer-Related Fatigue and Quality of Life Among Patients With High-Grade Glioma Society for Neuro-Oncology Musella Foundation End Brain Cancer Initiative Brain Tumor Network American Brain Tumor Association Glioblastoma Research Organization Brain Tumor Funders' Collaborative Optune Gio® website Nurse.org article: Mysterious Brain Tumor Cluster Grows: Another Nurse Diagnosed at Newton-Wellesley Lori Cappello's contact information: lori.cappello@hmhn.org To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “A glioblastoma actually is the most predominant brain tumor that we do see. It is the most diagnosed of the brain tumors. And then I would say that an anaplastic astrocytoma is probably the second diagnosed. Historically a GBM, they used to say was probably an elderly patient for these. But we are definitely seeing it diagnosed at a much younger age now, definitely much more prevalent for people under 60.” TS 3:17 “Nine times out of ten, either a patient out of nowhere has a seizure, or they present with what they think are stroke-like symptoms. They noticed that they were slurring, or they were becoming more forgetful, or a family member noticed it and said, ‘Hey, what is going on with you?' But usually they present to the [emergency department], and a [computed tomography] scan is always done first. And lo and behold, something is seen.” TS 4:50 “The only other U.S. Food and Drug Administration-approved treatment that has come along in the last 20 years is a device called Optune Gio, which is an alternating electric field that stops cell division at the mitosis stage.” TS 7:45 “They lose so much of their independence, especially if they don't have a caregiver or help. That is huge. Medication management at home, to making sure that they're taking the medication properly, that they are actually taking their medication. Transportation is another huge problem. Getting to and from appointments is a challenge. Those are big issues—real, day-to-day, simple issues that people don't think about.” TS 17:11 “I think that having a brain tumor is very unique in the fact that you really need a dedicated neuro-oncologist. And depending on where you live, there are not a lot in the area. I actually had a patient that was moving out west, and the closest dedicated neuro-oncologist was four hours from them. … if you're not seeing dedicated neuro oncologists, you might not be getting the best treatment for yourself. So I think that having the resources and helping patients find the best care or the best brain tumor society—and there's a bunch of really good brain tumor groups to help patients find the best resources out there. I think that's really, really important for patients to know or for families to know.” TS 19:17 “So trying to help patients, there are always going to be challenges, and there are always going to be ups and downs. But finding that one person that they can go to, that they trust, that they have a great relationship with, whether at the doctor's office or whatever, and being available to them makes such a difference in their journey. I think that that is the most important for anybody in the journey.” TS 22:08 “With brain, there are going to be expectations. They are going to lose functionality at some point—and preparing them for that thing or preparing them for things that can help themselves. Like sometimes I say, ‘Go to the dollar store, get coloring books,' if they have weakness in one hand. Little tricks of the trade that can help them. About treatment options, going through the side effects, preparing them for whatever they can be prepared for.” TS 22:39 “It is not one of the better cancers to have, but it doesn't immediately mean it's a death sentence, and we shouldn't treat them like they're dying. We shouldn't take away their ability to live just because they were diagnosed with it. We shouldn't take away hope.” TS 25:35 “I think there's not enough discussed about [brain malignancies] and the lack of resources for this. These patients need a lot more resources and are available. There's just not enough available for it.” TS 26:59

Welcome to another episode of the Great Business Minds podcast, the definitive show for the business of digital infrastructure. GBM is brought to you by Preiskel & Co, a leading award-winning City of London law firm, internationally recognised for its expertise in the digital infrastructure industry and the telecoms and tech sector work more broadly. Wherever your legal or regulatory needs are (including outer space) Preiskel & Co LLP can support you, so do feel free to reach out to them at www.preiskel.com. This week, Douglas Loewe, CEO of Kao Data, offers insights into the rapidly evolving landscape of data centre real estate and expansion, with a particular focus on the burgeoning artificial intelligence (AI) sector. As Loewe approaches his first anniversary at the helm of Kao Data, he reflects on the key milestones achieved in the company's roadmap. These achievements are set against the backdrop of an industry undergoing significant transformation, driven by the global AI arms race and the increasing demand for data centres engineered specifically for AI applications. The interview delves into Kao Data's strategic positioning within this competitive landscape. Loewe elucidates how the company is adapting its operations and future plans to meet the surge in demand for AI-capable infrastructure while simultaneously addressing critical issues of energy efficiency and sustainability. A significant portion of the discussion centres on the United Kingdom's role in the global AI ecosystem. Loewe offers his perspective on the unique advantages the country presents for data centre operators like Kao Data, highlighting the potential for growth and innovation within this dynamic market. The conversation also touches upon the economic climate and its impact on AI-related investments. Loewe provides insights into how Kao Data's strategy for attracting and allocating capital has evolved over the past year, reflecting the company's agility in responding to market trends and investor expectations. Looking towards the future, Loewe shares his vision for Kao Data over the next three to five years. He outlines what he perceives as the most significant challenges and opportunities facing the company, particularly in relation to the ongoing AI revolution and its implications for the data centre industry. Here at the GBM podcast, we hope you enjoy this episode and do leave us a review and share it with your contacts. We invite you back again for the next episode with another big name in the digital infrastructure space. If you want to get more from the definitive podcast for the business of digital infrastructure, make sure you subscribe to Great Business Minds. See you soon! /////////////////////// This episode features our commercial partner Preiskel & Co, a leading award-winning City of London law firm, internationally recognised for its expertise in the digital infrastructure industry as well as the telecoms and tech sector work more broadly. Visit www.preiskel.com for more information. /////////////////////// Get more from the GBM Podcast on: Official Website LinkedIn Facebook Instagram Twitter YouTube

BUFFALO, NY - April 4, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on March 27, 2025, titled “Imipridones ONC201/ONC206 + RT/TMZ triple (IRT) therapy reduces intracranial tumor burden, prolongs survival in orthotopic IDH-WT GBM mouse model, and suppresses MGMT." Researchers from Brown University, led by first author Lanlan Zhou and corresponding author Wafik S. El-Deiry, have shown that combining a new class of drugs called imipridones with standard glioblastoma treatments significantly improves outcomes in mice. The study tested ONC201 and its analog ONC206 in combination with radiation therapy and the chemotherapy drug temozolomide (TMZ), a regimen referred to as IRT. This triple therapy slowed tumor growth and extended survival in a mouse model of glioblastoma, offering a potential new strategy for one of the most aggressive and treatment-resistant brain cancers. Glioblastoma is a fast-growing brain tumor with a poor prognosis and limited treatment options. Standard care typically includes surgery, radiation, and TMZ, but most patients still face a short life expectancy. While ONC201 and ONC206 are currently being studied in clinical trials as single agents, there has been limited information on how they interact with standard therapies. This study is the first to show that both drugs work synergistically with radiation and TMZ, strengthening their overall effects. The results showed that in both laboratory-grown tumor cells and mice, the triple therapy significantly slowed cancer cell growth, reduced tumor size, and prolonged survival compared to using any single or double treatment. Mice treated with IRT lived an average of 123 days, with some surviving more than 200 days—far longer than the 44 to 103 days observed with other treatment combinations. In addition to directly killing tumor cells, ONC201 and ONC206 lowered the expression of MGMT, a protein that helps tumors resist chemotherapy, making the treatment more effective. The researchers also found that the triple therapy reshaped the tumor environment. It decreased levels of harmful molecules that promote tumor growth and immune evasion while increasing signals that activate the immune system. This dual action—directly attacking tumors and boosting immune responses—adds to the potential impact of this treatment approach. “Overall, our preclinical findings support further exploration of the ONC201 and ONC206 IRT regimen as a potential treatment for GBM and diffuse gliomas with H3K27M mutations.” While these findings are based on preclinical mouse models, they offer strong support for advancing this triple therapy to clinical trials. ONC201 and ONC206 are promising due to their ability to cross the blood-brain barrier and enhance the effects of standard treatment. This combination could lead to more effective therapies for glioblastoma and other hard-to-treat brain tumors. DOI - https://doi.org/10.18632/oncotarget.28707 Correspondence to - Wafik S. El-Deiry - wafik@brown.edu Video short - https://www.youtube.com/watch?v=Q_mXy8mana0 Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28707 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Topics covered : Cancer, Glioblastoma multiforme (GBM), control the controllables, shift in perspective, healthy body and mind, affirmations, positive self talk, appreciation. Alannah Sheehan lives in Tipperary with her husband Martin and their 3 children, Finn (9), Luca (7) and Phoebe (5).And 5 years ago when Phoebe was only a few months old, Alannah was diagnosed with Glioblastoma multiforme, an aggressive type of brain cancer.But today, 5 years on, she's healthy and happy and even though she still has to go for regular scans and deal with the stress and anxiety that goes with that, ultimately, life is good.We spoke 4 years ago but I wanted to chat to her again as she is so inspiring.In this conversation she talks about the power of taking control over what you can control and nourishing your body and mind, every day. Alannah was a chef before her diagnosis and food is her passion. Her go to juice is celery, cucumber and lemon and she drinks it every day.You can subscribe to Alannah's ‘Survive and Thrive' membership to gain access to her delicious recipes, and you can also purchase her gorgeous wellness cards too.Alannah SheehanInstagramALANNAH SHEEHAN (@worth_fighting4) • Instagram photos and videos If you're a fan of what I do, please follow, rate and review in all the usual places.And thanks, as always, for your support of Ready to be Real. Hosted on Acast. See acast.com/privacy for more information.

BUFFALO, NY - March 3, 2025 – A new #research paper was #published in Oncotarget, Volume 16, on February 28, 2025, titled “Effect of TIMPs and their minimally engineered variants in blocking invasion and migration of brain cancer cells." Elham Taheri and Maryam Raeeszadeh-Sarmazdeh from the University of Nevada, Reno, explored a new approach to slowing the spread of glioblastoma multiforme (GBM), the most aggressive and deadly form of brain cancer. Their study highlights the potential of both natural and engineered molecules to block cancer cell movement, offering a promising strategy to combat this challenging disease. Glioblastoma multiforme is difficult to treat because it quickly spreads into healthy brain tissue, making complete surgical removal nearly impossible. A major driver of this invasive behavior is a group of enzymes called matrix metalloproteinases (MMPs), which break down surrounding tissue and create space for cancer cells to spread. Among them, MMP-9 plays a particularly significant role in GBM progression and resistance to current treatments. To address this challenge, the researchers investigated tissue inhibitors of metalloproteinases (TIMPs), natural MMP blockers, and specially engineered versions designed for better effectiveness. The study used cell line models of GBM to test both TIMP-1 and TIMP-3 and their engineered counterparts (mTC1 and mTC3), specific blockers of MMP-9. “Our study focused on minimal TIMP variants, due to their small molecular size and potential in higher cellular uptake and delivery, to assess their potential in cell-based assays.” The results indicated that the engineered TIMPs were just as effective as, or even better than, the natural ones at reducing cancer cell migration and invasion. These findings are particularly promising because previous attempts to block MMPs with small-molecule drugs faced challenges such as poor selectivity and unwanted side effects. In contrast, these engineered TIMPs offer a more targeted and potentially safer approach. One of the greatest obstacles in treating brain cancer is delivering drugs across the blood-brain barrier, a protective layer that prevents many therapeutic compounds from reaching the brain. To address this, the researchers used cell-penetrating peptides to help the TIMP variants reach and enter cancer cells more effectively. Their results confirmed that the engineered TIMPs successfully reached tumor cells, further increasing their potential as a treatment. Additionally, the study found that these engineered TIMPs did not significantly affect healthy cells at lower doses, suggesting they could be used safely. This makes them strong candidates for further drug development. These findings could lead to new treatment options for GBM, a cancer with very few effective therapies. Future research will focus on testing these TIMP variants in animal models to evaluate their long-term effects and safety. Researchers also plan to investigate whether combining these engineered TIMPs with existing treatments, such as chemotherapy or immunotherapy, could improve outcomes. In summary, given the aggressive nature of GBM and the urgent need for better therapies, this study represents an important step forward. If further research confirms these results, engineered TIMPs could become a valuable tool in the fight against brain cancer, offering new hope for improved treatments and patient survival. DOI - https://doi.org/10.18632/oncotarget.28691 Correspondence to - Maryam Raeeszadeh-Sarmazdeh - maryamr@unr.edu Video short - https://www.youtube.com/watch?v=tdBlkOX50D8 To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

In February 2018, Rebecca Devine, a mum of 4 children, was diagnosed with Glioblastoma (GBM), an aggressive form of brain cancer, and given just 12-15 months to live.Remarkably in 2025 she's still here. And today we're going to talk about her incredible story from diagnosis and treatment, to continual perseverance and ongoing health.I met Rebecca recently at a small gathering hosted by Dr William Li for the angiogenesis foundation, a non profit whose mission is to beat cancer by targeting blood vessels that feed tumours. And it was there that I first came across her story that I'm privileged to share with you today.Today we'll talk about how Rebecca's first experience with cancer was over 20 years ago when her mother was struck with the same diagnosis, and the emotional and physical journey Rebecca went on since 2018. We'll talk about her blend of conventional therapy, diet and lifestyle pursuits as well as the novel vaccine based treatment that she currently uses to keep her condition in remission.Peptide vaccine technology is an emerging immunotherapy strategy aimed at stimulating the immune system to target tumor-specific antigens. GBM, is aggressive and resistant to standard therapies and peptide vaccines hold potential for transforming treatment by leveraging the immune system for tumor-specific targeting.I also firmly believe that the use of novel treatments combined with Rebecca's tenacity, mindset and unwillingness to give up is the reason why she's defied all odds and is currently thriving.

Check out this week's QuadCast as we highlight ideal adjuvant management of endometrial cancer from GOG 258, the best approach to locally recurrent rectal cancer, and also highlight recurrent GBM management guidelines. Welcome to 2025! Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom

Comedians Ari Shaffir & Adrienne Iapalucci join Big Jay Oakerson, Luis J. Gomez, & Dave Smith to discuss Luis' recent incident with an airplane phone talker, GBM's take on the Mike Tyson vs Jake Paul fight, and Dave's awkward situation regarding the purchase of a portrait of himself. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Original Air Date: 11/19/24Support our sponsors!Go to YoKratom.com - home of the $60 kilo!Fans over the age of 21, head to YoDelta.com and use promo code GAS for 25% off your order!Visit Autoblow.com and use promo code SKANKS for 10% off your first order!Download the PrizePicks app today and use code SKANKS for a first deposit match up to $100!Control Body Odor ANYWHERE with @shop.mando and get $5 off your Starter Pack (that's over 40% off) with promo code LEGION at ShopMando.com---------------

Comedians Derek Gaines & Brendan Sagalow join Big Jay Oakerson, Luis J. Gomez, and Dave Smith to discuss how GBM ended up with a black eye after a night of drinking, the Australian woman facing charges for filming an explicit video with a trout, and Luis and Jay's upcoming rap battle at Skankfest. Plus, the gang reviews entries into the "Worst Life" contest for Skankfest 2024 Golden Tickets. All This and More, ONLY on The Most Offensive Podcast on Earth, The LEGION OF SKANKS!!!Air Date: 08/27/24Support our sponsors!Go to YoKratom.com, home of the $60 kilo!Fans over the age of 21, head to YoDelta.com and use promo code GAS for 25% off your order!Head to SmallBatchCigar.com and use promo code LOS10 for 10% off your order plus 5% rewards points! Download the PrizePicks app today and use code SKANKS for a first deposit match up to $100! GET YOUR SKANKFEST VEGAS 2024 TICKETS HERE: SKANKFEST.COM